May 03, 2023 Press Release for Alnylam


Alnylam Issues 2022 Corporate Responsibility Report
May 03, 2023
– Successfully Met Goals Outlined in MassBio’s Diversity, Equity, and Inclusion (DE&I) Industry Pledge –
– New Disclosures of Company’s Impact on Planet—Including Multiyear Data on Scope 1, Scope 2, and Select Scope 3
“Our dedication to ethical and responsible business practices is a key enabler for our long-term success,” said
Key highlights from the 2022 report include:
-
Met all Diversity, Equity, and Inclusion (DE&I) goals in MassBio’s Industry pledge.
Launched formalU.S. supplier diversity program delivering on 2020 pledge to address inequity through six key areas: leadership and executive culture; inclusive company culture; recruitment; retention and development; accountability and sustainability; and supplier diversity.
-
Analyzed and published global multiyear data on Alnylam’s environmental impact.
Refined data collection process across scopes 1, 2, and select scope 3 GHG emissions to gather multiyear data and launched a new process to report water usage data for the first time.
-
Evolved approach to outreach and inclusion within clinical trials.
Trained clinical operations team, based in theU.S. andEurope , on cultural competency frameworks to better serve communities who have traditionally been excluded from clinical trials, as well as set diversity goals forAlnylam trials in common diseases.
-
Expanded Alnylam Challengers Health Equity
Initiative to Europe .
Partnered with innovative non-governmental organizations in theUK ,the Netherlands , andItaly to empower refugee populations to rebuild healthy, safe, and productive lives in their adopted homelands.
To learn more about corporate responsibility at
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20230503005131/en/
(Investors and Media)
617-682-4340
(Investors)
617-551-8276
Source:
For Media Inquiries, please contact:
Christine Lindenboom
SVP, Investor Relations & Corporate Communications media@alnylam.com 617-682-4340
For Investor Inquiries, please contact:
Josh Brodsky
VP, Investor Relations & Corporate Communications investors@alnylam.com 617-551-8276
MEDIA KIT
Essential assets and documents related to Alnylam